Kennis & ervaring
Specialisme / subspecialisme: Bottumoren en Lymfomen
Werkervaring:
2006 - 2014 Opleiding Kinderarts en Promotieonderzoek (Radboud umc)
2014 - 2016 Fellowship Kinderoncologie (Radboud umc)
2016 - 2018 Staflid Kinderoncologie (Radboud umc)
Wetenschappelijk:
Promotie: The role of pharmacogenetics in patients with osteosarcoma
Link naar pubmed: https://www.ncbi.nlm.nih.gov/pubmed/?term=hagleitner+mm
Age as prognostic factor in patients with osteosarcoma. Hagleitner MM, Hoogerbrugge PM, at al. Bone. 2011;49:1173-1177.
Survival trends and long term toxicity in pediatric patients with osteosarcoma. Hagleitner MM, de Bont ESJM, et al; Sarcoma. 2012:636405.
The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. Hagleitner MM, Coenen MJ, et al; Pharmacogenomics J. 2014;14:115-119.
First steps to personalized medicine in osteosarcoma: Pharmacogenetics as predictive marker of outcome after chemotherapy based treatment. Hagleitner MM, Coenen MJH, et al; Clin Cancer Res 2015;21(15):3436-41.
BIG-registratie
09062187801